Xintela AB (publ) is listed at Nasdaq First North Growth Market Stockholm per 2016-03-22.
Xintela's shares are traded under the name XINT (ISIN SE0007756903).
Following the latest subscription period for warrants of series TO3, which ended on June 5, 2024, the share capital is 17,062,815.27 SEK distributed over 568,760,509 shares. All issued shares are fully paid. The company’s share capital is expressed in Swedish crowns (SEK) and is distributed over the company’s issued shares with a quota value of 0.03 SEK per share.
Transactions performed by persons in senior positions are registered in accordance with EU rules on market abuse (MAR) in Finansinspektionen's transparency register.
No items found.
*Indicates warrents provided to employees/key individuals in the company after the share split that was decided at an extra AGM on November 27 2015, where the existing shares were split into 50 new shares. More information is available in the prospectus which was published by the company on January 29, 2016. The prospectus can be downloaded from the Report section below.
Interim Report, Q4 2023 – February 28, 2024
Annual Report 2023 – April, 2024
Annual General Meeting - May 8, 2024
Interim Report, Q1 2024 – May 24, 2024
Interim Report, Q2 2024 – August 30, 2024
Interim Report, Q3 2024 – November 22, 2024
Interim Report, Q4 2024 – February 28, 2025
BioStock's analysis partner Monocl Strategy Services has published its analysis of Xintela. The analysis was published on November 28, 2017 and focuses on Xintelas development of mesenchymal stem cell-based products for the treatment of cartilage and osteoarthritis, a condition that affects 333 million people only in the United States, Japan and the EU. In other words, there is an enormous clinical need for treatments for osteoarthritis, especially as current treatment paradigms focus primarily on relief of symptoms. From an analysis perspective, the overall conclusion is that Xintela is an exciting investment case that includes a diversified portfolio, great market potential and an interesting strategy to meet regulatory challenges.
Read moreArchive
Good corporate governance is critical to ensure that a company is managed in the correct manner. At Xintela, we are eager to have a good and clear corporate governance such that our investors trust the company and that the decisions that are made are well considered.
The Board and The Management Team
The Board are accountable for the company’s organisation and management and are the highest administrative structure below the General Meeting. The Management Team are appointed by the Board and their role is to manage the day to day operations of the company. Within the framework set out by the Board, the Management team can also manage, for example, company-wide matters and those of a strategic nature.
Read more about Xintela’s board and management team here.
Auditors
Öhrlings PricewaterhouseCoopers AB, 113 97 Stockholm have been the company’s auditors since 2010. The company’s primary auditor, since 2015, is Ola Bjärehäll, Box 2138, 22002 Lund.
Articles of association
The Articles of Association are the regulations by which a limited company are governed. Xintela’s Articles of Association can be downloaded here.
Subscribe to receive latest updates from Xintela straight to your inbox.
SubscribeFor any IR-related questions, please contact:
ir@xintela.se
Xintela’s certified adviser is:
Carnegie Investment Bank AB (publ)
Phone: +46 (0)73 856 42 65
E-mail: certifiedadviser@carnegie.se
